ThinkPatternGet the app
Story
BUSINESS · NOV 18, 2026

FDA Increases Unannounced Inspections of Indian Drug Plants

The US Food and Drug Administration has sharply increased unannounced audits of pharmaceutical facilities in India to improve safety oversight of generic drug exports.

The US Food and Drug Administration has significantly increased unannounced inspections of pharmaceutical facilities in India to enhance oversight of generic drug exports. In the fiscal year ending March 31, the agency conducted 87% of its audits in India without prior notice, a sharp increase from 47% in the preceding 12 months.

This shift in strategy removes the previous requirement to coordinate inspections through local public health authorities. The move follows quality concerns linked to Indian-made exports, including bacteria-laced eyedrops that killed four Americans and cough syrups linked to child deaths in Gambia and Uzbekistan. India provides approximately 40% of all generic medicines sold in the US.

Beyond audits, the agency plans to hold road shows in New Delhi and Hyderabad in May 2027. These events will focus on biosimilars, including anti-obesity therapies, as Indian firms expand their global supply of these drugs.


Reported across 3 outlets
Actors
US Food and Drug Administration

Keep reading in the app

The full story and every source, free in the app.